Anti CD19/CD22 chimeric antigen receptor T cell therapy - SPH Biotherapeutics
Latest Information Update: 16 Mar 2025
At a glance
- Originator SPH Biotherapeutics (Shanghai)
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Precursor B-cell lymphoblastic leukaemia-lymphoma